Clinical efficacy of andrographolide in treating children with primary nephrotic syndrome complicated with respiratory infection

doi:10.3877/cma.j.issn.1674-0785.2018.07.005

Abstract

Abstract:

Objective

To observe the clinical efficacy of andrographolide in treating children with primary nephrotic syndrome complicated with respiratory infection.

Methods

A total of 86 children with primary nephrotic syndrome complicated with respiratory infection treated at our hospital between March 2016 and March 2017 were included and randomly divided into either a control group or a study group. Both groups were given routine anti-infection therapy, and the study group was additionally given Xiyanping injection. The therapeutic effect and laboratory results were compared between the two groups using the t-test and X² test, respectively.

Results

The rate of significant improvement and the total effective rate in the study group were significantly higher than those in the control group (72.09% vs 53.49%, t=1.964, P=0.026; 97.67% vs 86.05%, t=1.832, P=0.048). After treatment, the leukocyte count, lymphocyte percentage, erythrocyte sedimentation rate, urinary glucosidase concentration, and urinary retinol binding protein concentration in the study group were significantly lower than those in the control group, while the concentrations of C-reactive protein and globulin were significantly higher than those of the control group (P<0.05). The percentages of CD3⁺ lymphocytes and CD4⁺ lymphocytes, CD4⁺ /CD8⁺ ratio, IgA, IgG, and IgM in the study group were significantly higher than those in the control group [(73.18±13.48)% vs (68.29±9.34)%, t=1.754, P=0.043; (30.18±4.52)% vs (27.26±4.27)%, t=1.749, P=0.039; (1.76±0.12) vs (1.37±0.26), t=2.484, P=0.008; (2.17±0.06) g/L vs (1.42±0.19) g/L, t=2.501, P=0.008; (6.31±0.97) g/L vs (5.06±1.17) g/L, t=1.767, P=0.048; (1.94±0.63) g/L vs (1.63±0.49) g/L, t=1.728, P=0.040].

Conclusion

Andrographolide has a curative effect in treating children with primary nephrotic syndrome complicated with respiratory infection. On the basis of anti-infective therapy, andrographolide can improve the cellular immunity and humoral immunology index.

Key words: Andrographolid, Primary nephrotic syndrome, Respiratory Infection, Children

Pei Zhang, Zhengkun Xia. Clinical efficacy of andrographolide in treating children with primary nephrotic syndrome complicated with respiratory infection[J]. Chinese Journal of Clinicians(Electronic Edition), 2018, 12(07): 394-399.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2018.07.005

https://zhlcyszz.cma-cmc.com.cn/EN/Y2018/V12/I07/394

Figures/Tables 5

References 21

1	Robson WL, Leung AK. Nephrotic syndrome in childhood [J]. Adv Pediatr, 1993, 40:287-323
2	Eddy AA, Symons JM. Nephrotic syndrome in childhood [J]. Lancet, 2003, 362(9384):629-639.
3	Wong W. Idiopathic nephrotic syndrome in New Zealand children, demographic, clinical features, initial management and outcome after twelve-month follow-up: results of a three-year national surveillance study [J]. J Paediatr Child Health, 2007, 43(5):337-341.
4	El Mashad GM, El Hady Ibrahim SA, Abdelnaby SAA. Immunoglobulin G and M levels in childhood nephrotic syndrome: two centers Egyptian study [J]. Electron Physician, 2017, 9(2):3728-3732.
5	Jayakumar T, Hsieh CY, Lee JJ, et al. Experimental and Clinical Pharmacology of Andrographis paniculata and Its Major Bioactive Phytoconstituent Andrographolide [J]. Evid Based Complement Alternat Med, 2013, 3(24):846740.
6	Lim JC, Chan TK, Ng DS, et al. Andrographolide and its analogues: versatile bioactive molecules for combating inflammation and cancer [J]. Clin Exp Pharmacol Physiol, 2012, 39(3):300-310.
7	Cabrera D, Wree A, Povero D, et al. Andrographolide Ameliorates Inflammation and Fibrogenesis and Attenuates Inflammasome Activation in Experimental Non-Alcoholic Steatohepatitis [J]. Sci Rep, 2017, 7(1):3491.
8	中华医学会儿科学分会肾脏病学组. 小儿肾小球疾病的临床分类、诊断及治疗 [J]. 中华儿科杂志, 2001, 39(12):746-747.
9	江载芳，申昆玲，沈颖. 诸福棠实用儿科学[M]. 8版. 北京: 人民卫生出版社, 2015: 1231-1249.
10	中华医学会儿科学分会肾脏病学组. 儿童常见肾脏疾病诊治循证指南(一) [J]. 中华儿科杂志, 2009, 43(3):167-170.
11	中华医学会儿科学分会肾脏病学组. 儿童常见肾脏疾病诊治循证指南(三) [J]. 中华儿科杂志, 2010, 48(1):72-75.
12	陈永红. 儿科疾病诊断与疗效标准 [M]. 上海: 上海中医药大学出版社, 2006: 75-84.
13	Shao ZJ, Zheng XW, Feng T, et al. Andrographolide exerted its antimicrobial effects by upregulation of human β-defensin-2 induced through p38 MAPK and NF-κB pathway in human lung epithelial cells [J]. Can J Physiol Pharmacol, 2012, 90(5):647-653.
14	Peng S, Gao J, Liu W, et al. Andrographolide ameliorates OVA-induced lung injury in mice by suppressing ROS-mediated NF-κB signaling and NLRP3 inflammasome activation[J]. Oncotarget, 2016, 7(49):80262-80274.
15	Basha KA, Raman RP, Prasad KP, et al. Effect of dietary supplemented andrographolide on growth, non-specific immune parameters and resistance against Aeromonas hydrophila in Labeo rohita (Hamilton) [J]. Fish Shellfish Immunol, 2013, 35(5):1433-1441.
16	Wen L, Xia N, Chen X, et al. Activity of antibacterial, antiviral, anti-inflammatory in compounds andrographolide salt [J]. Eur J Pharmacol, 2014, 10(5):421-427.
17	汪忠鸿，张翼飞. 喜炎平雾化吸入治疗手足口病的临床研究 [J]. 世界最新医学信息文摘, 2014, 14(35):185-186.
18	Bera R, Ahmed SK, Sarkar L, et al. Pharmacokinetic analysis and tissue distribution of andrographolide in rat by a validated LC-MS/MS method [J]. Pharm Biol, 2014, 52(3):321-329.
19	Ji X, Li C, Ou Y, et al. Andrographolide ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated renal oxidative stress and inflammation via Akt/NF-κB pathway [J]. Mol Cell Endocrinol, 2016, 12(437):268-279.
20	Lan T, Wu T, Gou H, et al. Andrographolide suppresses high glucose-induced fibronectin expression in mesangial cells via inhibiting the AP-1 pathway [J]. J Cell Biochem, 2013, 114(11):2562-2568.
21	Das S, Periyasamy R, Pandey KN. Activation of IKK/NF-κB provokes renal inflammatory responses in guanylyl cyclase/natriuretic peptide receptor-A gene-knockout mice [J]. Physiol Genomics, 2012, 44(7):430-442.

组别	例数	性别（男/女）	年龄（岁，±s）	体质量（kg，±s）	病程（d，±s）
治疗组	43	24/19	7.79±6.19	25.71±12.48	4.87±2.66
对照组	43	23/20	7.84±6.33	26.14±13.19	4.51±3.12
统计值	?	χ²=0.102	t=0.924	t=0.646	t=1.141
P值	?	0.75	0.126	0.261	0.083

组别	例数	性别（男/女）	年龄（岁，±s）	体质量（kg，±s）	病程（d，±s）
治疗组	43	24/19	7.79±6.19	25.71±12.48	4.87±2.66
对照组	43	23/20	7.84±6.33	26.14±13.19	4.51±3.12
统计值	?	χ²=0.102	t=0.924	t=0.646	t=1.141
P值	?	0.75	0.126	0.261	0.083

组别	例数	病原体分布				病灶分布
组别	例数	细菌	病毒	支原体	真菌	上呼吸道感染	支气管炎	支气管肺炎	肺炎
治疗组	43	36（83.72）	27（62.79）	15（34.88）	2（4.65）	9（20.93）	14（32.56）	10（23.26）	8（18.60）
对照组	43	32（74.42）	30（69.77）	12（27.91）	2（4.65）	9（20.93）	14（32.56）	10（23.26）	8（18.60）

组别	例数	病原体分布				病灶分布
组别	例数	细菌	病毒	支原体	真菌	上呼吸道感染	支气管炎	支气管肺炎	肺炎
治疗组	43	36（83.72）	27（62.79）	15（34.88）	2（4.65）	9（20.93）	14（32.56）	10（23.26）	8（18.60）
对照组	43	32（74.42）	30（69.77）	12（27.91）	2（4.65）	9（20.93）	14（32.56）	10（23.26）	8（18.60）

组别	例数	发热	咳嗽、喘息	咽痛	流涕	扁桃体肿大	肺部啰音	水肿
治疗组	43	4.24±1.16	6.07±0.79	3.16±0.89	3.68±0.82	5.46±1.23	6.22±1.43	7.79±1.54
对照组	43	5.91±0.98	6.28±0.84	4.05±1.22	3.93±1.31	5.37±1.45	8.04±2.19	9.18±2.05
t值	?	1.783	0.584	1.742	0.673	0.657	1.861	2.596
P值	?	0.042	0.249	0.039	0.274	0.268	0.028	0.008

Please choose a citation manager

Content to export